Technology Evaluation Agreement and Patent Application
Melbourne, Sep 1, 2016 AEST (ABN Newswire) - Bluechiip Ltd (
ASX:BCT), a leader in the development of sample tracking technology for harsh environments, today announced the signing of a Technology Evaluation Agreement with a major automatic identification and data capture company in the USA's mid-west and the filing of a provisional patent application for an "over-temperature chip".
Technology Evaluation Agreement
The agreement, including a developer kit will allow the company to test and assess Bluechiip's technologies in high-value harsh-environment applications in biobanking and other applications, including aerospace.
The announcement comes on the back of similar sales made to the Chinese Centre for Disease, Control and Prevention, based in Beijing, and a major consumables company in North America.
Bluechiip CEO Andrew McLellan said, "Each Evaluation agreement or sale of a developer kit sales reinforces the demand that we know exists for better tracking technologies, particularly in harsh, high-value industries like biobanking. Such sales generate initial revenue for Bluechiip but more importantly increase our potential pipeline for further sales through conversion to long term supply agreements."
Provisional patent application for an "over-temperature chip"
Bluechiip also announced today the filing of a provisional patent application resulting from its government co-funded Research-Connections development project with the University of Melbourne's Centre for Neural Engineering. The patent application covers a new technology which provides a permanent record if a sample's temperature, once frozen, deviates above an ideal prescribed limit causing damage and potential failure.
"This new technology comes after multiple specific requests from end customers," Mr McLellan said. "The new provisional patent application is a very exciting development for us, and has the potential to increase the sales value of Bluechiip's chip ten-fold. An "overtemperature chip" provides a significant springboard into adjacent markets outside of biopreservation, especially into pharmaceuticals and cold chain logistics markets. Conversion to a genuine product is on Bluechiip's medium-term roadmap."
About Bluechiip Limited
Bluechiip Ltd (ASX:BCT) understands that every sample - stem cells, blood, eggs, sperm and other biospecimens - is critical, so our objective is to manage each one with optimal quality in the most efficient way. Bluechiip's advanced management solution is the only one that provides sample temperature with ID in cryogenic environments to. Most importantly, this delivers confidence in every sample.
Bluechiip's unique patented technology is a MEMS-based wireless tracking solution that contains no electronics. It represents a generational change from current tracking methods such as labels (hand-written and pre-printed), barcodes (linear and 2D), and Radio Frequency Identification. Bluechiip tags are either embedded or manufactured into storage products such as vials or bags. Each product can be easily identified, and critical information such as sample temperature, is detected by readers and stored in the Bluechiip software. In addition to functioning in extreme temperatures, the Bluechiip(R) Advanced Sample management solution can survive autoclaving, gamma irradiation sterilization, humidification, centrifuging, cryogenic storage and frosting.
Bluechiip's technology has applications in healthcare, including in cryogenic storage facilities (biobanks and biorepositories), pathology, clinical trials and forensics. Other key markets include cold-chain logistics/supply chain, security/defence, industrial/manufacturing and aerospace/aviation.
Bluechiip: Delivering confidence in every sample.
| ||
|
